Teva Must Surrender Generics To Get Cephalon: FTC

Law360, New York (October 7, 2011, 8:02 PM EDT) -- The Federal Trade Commission announced Friday it will require Teva Pharmaceutical Industries Ltd. to sell the rights to a generic cancer pain drug and generic muscle relaxant as conditions of its $6.8 billion acquisition of drug firm Cephalon Inc.

The rights and assets of the generic versions of Teva's cancer pain drug, Actiq, and muscle relaxant, Flexeril, must be sold to New Jersey-based generic drug manufacturer Par Pharmaceutical Inc. within 10 days of the acquisition, the FTC said.

In addition, the commission will require Teva to...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.